To see all protocols that comply with the WHO Essential Medicine List 
 Blood transfusion warning:

Interference with indirect antiglobulin tests may occur. Please notify your blood transfusion laboratory and send a blood sample for extended red blood cell phenotype and RBC antibody screen BEFORE the first dose of daratumumab.

If an emergency transfusion is required, non-cross-matched ABO/RhD-compatible RBCs can be given as per local blood bank practices. Please refer to the ANZSBT/MSAG position paper.  r

This protocol is different from daratumumab monotherapy. It is intended for daratumumab maintenance following chemotherapy administration. 

Patients with myeloma should be considered for inclusion into clinical trials. Link to ALLG website and ANZCTR website.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

19 Sep 2021